ASMS 2026: Oligonucleotide LC-MS Impurity Analysis with Trace Peak and Progressive Deconvolution
Vendor-neutral Byos Oligo workflow comparing UV, MS, and UV-MS quantitation across high- and low-resolution oligo datasets
About this Poster
Oligonucleotide therapeutics demand the same impurity-detection rigour as biologics, but the LC-MS data is messier and the impurity space (clips, shortmers, longmers, substitutions, chemical modifications) is much wider. This poster shows how Byos Oligo automates impurity analysis across the full dataset complexity range — running both Trace Peak (TP) and Progressive Deconvolution (PD) workflows on a high-resolution Agilent DNA 40-mer, plus low-resolution single-quad data on a 9 kDa oligonucleotide, using one consistent template-driven workflow.
Key Learnings:
- See how one Byos Oligo workflow runs on both high-resolution Orbitrap-class data and low-resolution single-quad data with minimal adjustments.
- Compare Trace Peak versus Progressive Deconvolution: TP is simpler and faster for high-throughput; PD detects very low-abundance impurities thanks to signal-processing noise reduction.
- Understand three relative-quantitation approaches — UV-only, MS-only, and the hybrid UV-MS — and where each estimates FLP purity differently (90% UV-only vs 70% UV-MS on the same sample).
- Learn how automated template-driven reporting closes the loop from raw LC-MS to a delivered impurity report, including >100 impurity masses for the DNA 40-mer dataset.
Public Agilent DNA 40-mer LC-HRMS dataset used for high-resolution comparison.